pared for their capacity to survive challenges with the C3H-derived fibrosarcoma BP8. It was found:
(1) The tumour grows at the same rate with the same median survival time in matched groups of non-immunized mice from both strains after i.p. injection of tumour cells.
(2) Cyclophosphamide (Cyclo) at 10 mg/kg will cure CBA mice which have received i.p. injections of 107 BP8, but this dose, and more intensive treatment with this drug, fails to cure C3H mice.
(3) Injecting 125IUdR-labelled tumour cells and counting 125I loss by whole-mouse counting shows that the cytotoxic effect of Cyclo against BP8 is similar in the 2 mouse strains.
(4) Cyclo itself does not cure CBA mice, for viable tumour cells are recoverable from the peritoneal cavity 10 days after CBA mice have received 107 BP8 followed by 10 mg/ kg Cyclo. (5) CBA mice cured of BP8 ascites by Cyclo treatment will reject further i.p. inocula of BP8.
(6) The strength of immunity induced by irradiated BP8 cells was directly related to the length of exposure to this antigen. An important aspect of Cyclo treatment is that it prolongs the period during which immunity may develop. (7) Immunization of CBA mice with heavily irradiated BP8, with or without Cyclo, failed to show that Cyclo depressed the capacity of CBA mice to develop cytotoxic immunity. There was some indication that animals immunized with irradiated cells plus drug did better than those with irradiated cells alone. (8) A single injection of irradiated BP8 cells into CBA mice induced weak cytotoxic immunity, as assessed by destruction of a subsequent challenge with BP8, but these mice died from tumour more rapidly than non-immunized controls. It is suggested from these data that immunological enhancement may not always be due to blocking of cytotoxic immunity.
THERE ARE NOW a number of studies on cytotoxic immunity. There are several the combined effects of anti-tumour im-ways in which synergy between drug munity and cytotoxic drugs (Mihich, treatment Fisher et at., 1975) . However, in tumour cells; (2) drugs may actually some instances it has been difficult to potentiate cytotoxic immunity by indistinguish the cytotoxic effect of the terfering with regulatory mechanisms drug on the tumour from the effect of (Askenase et al., 1975; Otterness and Chang, 1976) (Porteous and Munro, 1972; Chassoux et al., 1977 Heparinized Minimum Essential Medium (MEM) was injected i.p. The cell-containing medium was recovered through an abdominal incision with a Pasteur pipette. A second lot of medium was then added to the peritoneal cavity and the cell suspension recovered. Cells were centrifuged and resuspended in MEM. The cell concentration was adjusted to 107/ml for injection into test animals.
Labelling tumour cells-.The method is that described by Porteous and Munro (1972) Chemotherapy.-Cyclophosphamide (Endoxana-WB Pharmaceuticals Ltd., Bracknell) (Cyclo) was injected i.v. in 01 ml into the retro-orbital sinus of mice under ether anaesthetic.
Drug was injected 1 h after the labelled cells.
Irradiation.-Cell suspensions were adjusted to 107/ml in heparinized MEM. They were irradiated from a cobalt source at a calculated rate of 100 rad/min for 12 min. The cells were injected within 2 h of irradiation.
RESULTS
The Four experiments where survival times were directly compared between C3H and CBA mice. The BP8 used in each experiment were prepared as a single batch for injection into both strains of mice.
injected i.p. with BP8. Ten mg/kg of i.v. Cyclo 1 h after an i.p. injection of 107 BP8 prevented 10/11 CBA mice from developing fatal ascites tumour. However, none of a range of doses of Cyclo to C3H mice after injection of 107 BP8 stopped death from the tumour (Table II) . It will be seen that 10 mg/kg of i.v. Cyclo produced as great an increase in survival time as larger or multiple doses of drug. This observation is reflected in the rate of tumour-cell destruction by drug, as assessed by loss of 1251 from mice injected with IUdR-labelled tumour cells (Fig. 1) .
The increase in survival achieved in these experiments was not improved when tumour was given as a small inoculum of 5 x 103 tumour cells, and 10 mg/kg of Cyclo was given 5 days later. After 5 days, 5x 106 tumour cells were recoverable from the peritoneal cavity. Five x 106 125IUdR-labelled BP8 were given 1 h before the drug, to allow its cytotoxic effect to be followed.
Is the cytotoxic effect of cyclophosphamide on BP8 similar in CBA and C3H mice?
It was possible that Cyclo might have been converted to active metabolites more efficiently in CBA than in C3H mice. To assess the relative cytotoxicity of this drug on the tumour in these 2 strains, the rate of 1251 excretion from mice injected with 125IUdR-labelled BP8 was assessed. Table  III Immunization was with 107 irradiated cells (12,000 rad). Drug was given 1 h later. After 28 days all mice were challenged with 107 125IUdR-labelled tumour cells. The survival of the group receiving irradiated cells without drugs was less than that of non-immune controls (P<0 *05) and mice receiving irradiated cells+ drugs P< 0 -01 (2-tailed Wilcoxon rank-sum test on pooled results of the 2 experiments). The 125I excretion was greater in the two immunized groups than the non-immune group in both experiments on Days 3-9 after challenge (P<0-01; two-tailed t test on log percent 125I retained). of irradiated BP8 by pre-labelling the tumour cells with 125IUdR before injection into CBA mice (Fig. 3) . Whilst cells irradiated in this way do not grow to form ascites, their rate of death is considerably less rapid than that of cells killed by other techniques such as freezing and thawing, in which over 95 % of the isotope is lost by 48 h (Falcao et al., 1977 Otterness and Chang (1976) showed an increase in T-cell cytotoxicity against a syngeneic tumour in mice after a single dose of 10 mg/kg of Cyclo, given at the same time as tumour cells. However, different timings and doses of drug reduced T-cell cytotoxicity. Askenase et al. (1975) showed an increase in delayed hypersensitivity reactions to sheep red cells when mice were tested 10 days after receiving 20 mg/kg of Cyclo. These mice had been given a primary immunization the day after the drug. Finerty and Krehl (1976) also showed potentiation of immunity in mice against plasmodium following Cyclo treatment. On the other hand, there are also many references in which Cyclo has been shown to be an active immunosuppressive agent (Berenbaum, 1975) . If Cyclo is potentiating immunity, a number of possible mechanisms come to mind. Firstly the potentiation may simply be due to the drug preserving antigen in a non-lethal form for many days within the animal. The increased immunity seen when 3 immunizations with heavily irradiated cells are used, compared with one, indicates that length of antigen exposure is an important factor, and this alone may provide an adequate explanation for the good immunity seen after Cyclo. It is also possible that the drugs may modify the antigenicity of the tumour cells to increase their immunogenicity. Such an effect has been recorded for tumour cells exposed to ionizing irradiation (Haddow and Alexander, 1964; Mathe et al., 1969; Bomford, 1975; McBurney, 1976) . Alternative mechanisms of potentiation include the modification of antigen processing or the inhibition of homoeostatic mechanisms (Ramshaw et al., 1976) . CBA mice given a single i.p. immunization with heavily irradiated BP8 show clear evidence of weak cytotoxic immunity, as assessed by 1251 loss, against a subsequent challenge of live BP8 cells (Table  IV) . However, these mice die significantly more rapidly from tumour than nonimmunized mice do. This paradoxical result poses a number of interesting questions. Firstly does this finding mean that increased 1251 loss in this instance is not reflecting true tumour-cell destruction? There are many reasons for delay in 1251 loss from mice following destruction of 125IUdR-labelled tumour cells, including phagocytosis of dead cell debris, uptake of iodide by the thyroid, and impaired renal excretion. However, it is difficult to think of reasons for falsely high rates of 1251 loss, other than injection of tumour into the gut. This gives a far more rapid loss of isotope than that seen in the immunized group of mice. In interpreting these data, one has to remember that BP8 is a rapidly dividing tumour. Mean cell-cycle times during the initial exponential growth phase after i.p. injection are around 12-14 h. Consequently, whilst 20% 1251 excretion during the first day after the injection of 107 125IUdR-labelled BP8, reflects death of 2x 106 cells, the same percentage loss 2 days later might reflect the death of 2 x 107 cells. The tumour-cell destruction rates in the mice immunized with a single injection of irradiated BP8 (Fig. 3) are never great enough to counter the exponential growth potential of BP8. Consequently, cure by this level of cytotoxic immunity would not be expected. Despite these arguments one still has to explain the more rapid death in mice immunized with irradiated cells than in controls. The way in which this tumour kills the host is not fully clear. In common with other experimental tumours, exponential growth does not continue indefinitely. Here the maximum number of tumour cells recoverable from the peritoneal cavity is between 5 and 8 x 108 cells, and before death this number often falls. It would seem reasonable to postulate that the rapid death in mice immunized in this way is related to alterations in the poorly understood events occurring when net tumour growth has effectively stopped. Without the use of 125IUdR studies the reduced survival time associated with immunization might have been attributed to blocking of cytotoxic immunity. These studies suggest that immunological enhancement in some instances may be attributable to quite different mechanisms.
